ClinGen Dosage Sensitivity Curation Page

DLG2

Curation Status: Complete

Gene Information

Location Information

Evidence for Loss Phenotypes

Evidence for loss of function phenotype
PubMed ID Description
21792059 Sahoo et al. 2011- evaluation of individuals with copy number variants, identified by microarray testing, overlapping known schizophrenia susceptibility loci. Found five instances of partial DLG2 deletions in individuals with varying indications, three had delays.
25055870 Georgieva et al. 2014 - microarray study of 368 individuals with bipolar disorder, found a de novo partial deletion of DLG2 in a patient with bipolar disorder.
18511947 Xu et al. 2008 - SNP array done on patients with the only case of schizophrenia in their close family members, found a de novo 269kb partial deletion of DLG2.

Evidence for Triplosenstive Phenotype

NOTE:The loss of function score should be used to evaluate deletions, and the triplosensitivity score should be used to evaluated duplications. CNVs encompassing more than one gene must be evaluated in their totality (e.g. overall size, gain vs. loss, presence of other genes, etc). The rating of a single gene within the CNV should not necessarily be the only criteria by which one defines a clinical interpretation. Individual interpretations must take into account the phenotype described for the patient as well as issues of penetrance and expressivity of the disorder. ACMG has published guidelines for the characterization of postnatal CNVs, and these recommendations should be utilized (Genet Med (2011)13: 680-685). Exceptions to these interpretive correlations will occur, and clinical judgment should always be exercised.